AUROPHARMANSEQ4FY25May 26, 2025

Aurobindo Pharma Limited

2,258words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
ny Code No. AUROPHARMA To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 Dear Sir / Madam, Sub: Inve
₹ 8,382
ncial Highlights 4 Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7
₹ 1,792
ghts 4 Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Busine
₹ 903
Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlig
₹ 7,979
hts of the Quarter Revenue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highes
₹ 1,628
uarter Revenue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highest ever quart
₹ 846
nue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highest ever quarterly reven
5.1%
Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highest ever quarterly revenues of ₹8,382 Crores wit
10.1%
₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highest ever quarterly revenues of ₹8,382 Crores with 5.1%
6.7%
82 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highest ever quarterly revenues of ₹8,382 Crores with 5.1% growth
₹8,382 Crore
-Q growth % 5.1% 10.1% 6.7% 5 Business Highlights – Q4FY25 Highest ever quarterly revenues of ₹8,382 Crores with 5.1% growth QoQ Highest ever quarterly EBITDA with a good margin of 21.4%, driven by gross m
21.4%
revenues of ₹8,382 Crores with 5.1% growth QoQ Highest ever quarterly EBITDA with a good margin of 21.4%, driven by gross margins and operating efficiencies Net Capex of US$ 90 million* primarily toward
Advertisement
← All transcriptsAUROPHARMA stock page →